FDA Approved: RYSTIGGO — Original Application (UCB, Inc.)

View source ↗

Summary

The FDA approved RYSTIGGO (rozanolixizumab) for the treatment of adults with generalized myasthenia gravis, marking the first approval of this FcRn inhibitor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• RYSTIGGO (rozanolixizumab)

Snippet

ORIG AP for RYSTIGGO (ROZANOLIXIZUMAB)